Immunome Inc
IMNM8.680USD
-0.240-2.69%
收盤 06/25, 16:00（美東）報價延遲15分鐘
754.78M總市值
虧損本益比TTM
關於 Immunome Inc 公司
Immunome, Inc. 是一家致力於開發靶向癌症療法的生物技術公司。該公司的產品組合採用適合其生物學的模式來追求每個目標，包括免疫療法、放射性配體療法和抗體-藥物偶聯物 (ADC)。其記憶性 B 細胞雜交瘤技術可用於篩選和功能表徵新型抗體和靶點。其項目包括腫瘤學 (IMM-ONC-01)、LU FAP 和 SARS-CoV-2 (IMM-BCP-01)。腫瘤學項目是一種針對白細胞介素-38 (IL-38) 的抗體 (IMM-ONC-01)，這是一種用於治療各種實體瘤的新型免疫調節劑。其靶向效應器平臺使用小分子配體選擇性地將藥物有效載荷遞送至患病細胞。該公司還運營 AL102 和相關候選藥物 AL101。AL102 是一種研究性小分子伽馬分泌酶抑制劑，目前正在 III 期評估其用於治療纖維瘤的效果。 AL102 是一種潛在的每日一次口服治療纖維瘤的藥物。
公司簡介
公司代碼IMNM
公司名稱Immunome Inc
上市日期Oct 02, 2020
成立日期2015
CEODr. Clay B. Siegall, Ph.D.
員工數量118
證券類型Ordinary Share
年結日Oct 02
公司地址18702 N. Creek Parkway
城市BOTHELL
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編98011
電話16103213700
網址https://immunome.com/
公司代碼IMNM
上市日期Oct 02, 2020
成立日期2015
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Sandra M Swain, M.D.
Dr. Sandra M Swain, M.D.
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
收入明細
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
暫無數據
地區USD
名稱
營收
佔比
United States
9.04M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
股東類型
持股股東
佔比
Investment Advisor
33.48%
Investment Advisor/Hedge Fund
29.43%
Hedge Fund
14.85%
Corporation
8.26%
Research Firm
4.28%
Individual Investor
3.23%
Venture Capital
0.91%
Bank and Trust
0.29%
Pension Fund
0.14%
Other
5.14%
機構持股
更新時間: 3月3日 週一
更新時間: 3月3日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
295
69.73M
91.15%
+848.96K
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
2023Q1
95
4.18M
34.54%
-644.30K
2022Q4
98
4.36M
36.09%
-940.25K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
T. Rowe Price Investment Management, Inc.
5.50M
6.33%
-262.06K
-4.55%
Dec 31, 2024
Redmile Group, LLC
4.83M
5.55%
-61.53K
-1.26%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.74M
4.3%
+134.54K
+3.73%
Dec 31, 2024
Enavate Sciences GP, LLC
3.48M
4%
+3.48M
--
Dec 31, 2024
The Vanguard Group, Inc.
3.00M
3.45%
-128.13K
-4.10%
Dec 31, 2024
EcoR1 Capital, LLC
3.88M
4.46%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
3.92M
4.51%
-305.48K
-7.23%
Dec 31, 2024
Opaleye Management Inc.
2.04M
2.35%
+802.50K
+64.85%
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
WisdomTree BioRevolution Fund
0.97%
iShares Genomics Immunology and Healthcare ETF
0.71%
ALPS Medical Breakthroughs ETF
0.63%
Virtus LifeSci Biotech Clinical Trials ETF
0.5%
Main Thematic Innovation ETF
0.5%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Nuveen ESG Small-Cap ETF
0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
0.05%
查看更多
WisdomTree BioRevolution Fund
佔比0.97%
iShares Genomics Immunology and Healthcare ETF
佔比0.71%
ALPS Medical Breakthroughs ETF
佔比0.63%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.5%
Main Thematic Innovation ETF
佔比0.5%
SPDR S&P Biotech ETF
佔比0.2%
iShares Micro-Cap ETF
佔比0.15%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.13%
Nuveen ESG Small-Cap ETF
佔比0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
